FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation By Ogkologos - November 20, 2025 245 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KO-MEN-001 study Source RELATED ARTICLESMORE FROM AUTHOR Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma MOST POPULAR Taking Control – Risks vs. Benefits July 14, 2020 A Poet’s Autobiography of Cancer May 31, 2023 Mom Battling Cancer Lets 4-Yr-Old Give Her “Best Haircut Ever.” December 6, 2019 BRCA1/2 Pathogenic Variant Carriers with Serous Tubal Intraepithelial Carcinoma at Risk-Reducing... April 4, 2022 Load more HOT NEWS ΚΑΡΚΙΝΟΣ ΤΟΥ ΜΑΣΤΟΥ “Glossy” Awareness Campaigns Weren’t Representing Her Cancer, So She Started #TrueCancerBodies Opinion: “There’s cause for optimism in 2021 and beyond” Increasing Education About Cancer Screening and Prevention in Kazakhstan
